The nuclear medicine group of Siemens Medical Systems has startedbuilding the first gamma camera detectors using sodium iodidecrystals grown at a new facility the vendor has built at its HoffmanEstates, IL, headquarters. The new crystal-growing factory
The nuclear medicine group of Siemens Medical Systems has startedbuilding the first gamma camera detectors using sodium iodidecrystals grown at a new facility the vendor has built at its HoffmanEstates, IL, headquarters. The new crystal-growing factory isexpected to improve Siemens' nuclear medicine R&D effort andwill reduce the company's dependence on French chemical consortiumSaint-Gobain, which was the only manufacturer of the crystalsin the world until the Siemens program came online, accordingto Paul Kasulis, director of new business units.
Siemens announced at last year's Society of Nuclear Medicinemeeting that it had acquired crystal-growing technology from theUkrainian Institute for Single Crystals in Kharkov and was transferringUkrainian engineers to the U.S. to create its own supply. At thisyear's SNM conference, Siemens said it had built the first detectorsusing the crystals and would begin life-cycle testing of the devices.The company expects to begin production shipments of cameras withthe home-grown crystals in the fall, Kasulis said.
Using crystals of its own manufacture confers a number of advantagesbeyond just self-sufficiency, according to Kasulis. Siemens willnow be able to design crystals to its own specifications for specializeduses such as high-energy imaging or organ-specific applications.
"They will be used commercially, but the windfall is toget crystals pre-commercial -- in other words, to get crystalsto do whatever you want on a research basis," Kasulis said.
Siemens will also supply its crystals to nuclear medicine researchers,as well as other gamma camera vendors. The company has receivedgood manufacturing practices (GMP) approval for the crystal-growingplant and the nuclear medicine group has ISO 9000 certification.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.